Literature DB >> 12530944

Interaction of iron, insulin resistance, and nonalcoholic steatohepatitis.

Shivakumar Chitturi1, Jacob George.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) has emerged as a ubiquitous liver disorder with occasional serious overtones. Although diabetes and obesity were initially held culpable, insulin resistance (IR) is now considered the fundamental operative mechanism. IR is probably the "first step" in nonalcoholic steatohepatitis (NASH). Oxidative stress may be the elusive "second" of possibly multiple steps in the progression of steatosis to fibrosing steatohepatitis. Because hepatic iron promotes oxidative stress, it was mooted as a contributory cofactor in NASH. This proposal was strengthened by an association with hepatic fibrosis. Subsequent studies have shown neither a significant increase in hepatic iron nor an association between hepatic iron and any of the histologic determinants in NASH. Likewise, the increased prevalence of hemochromatosis gene (HFE) mutations in some studies appears to be largely irrelevant to the development of hepatic fibrosis. Excess hepatic iron may occur in insulin resistance-associated iron overload (IRHIO), characterized by hyperferritinemia with normal to mild increases in transferrin saturation. Although patients with IRHIO have a high prevalence of IR-related metabolic disorders, the relationship of IRHIO to NASH is unclear. A recent study showed improvement in insulin sensitivity with the use of venesection in patients with NAFLD, but this approach cannot be implemented without extensive review.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12530944     DOI: 10.1007/s11894-003-0005-y

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  51 in total

Review 1.  More clues to the relationship between hepatic iron and steatosis: An association with insulin resistance?

Authors:  G A Macdonald; L W Powell
Journal:  Gastroenterology       Date:  1999-11       Impact factor: 22.682

Review 2.  Nonalcoholic fatty liver disease: an agenda for clinical research.

Authors:  Zobair M Younossi; Anna Mae Diehl; Janus P Ong
Journal:  Hepatology       Date:  2002-04       Impact factor: 17.425

Review 3.  Nonalcoholic fatty liver disease.

Authors:  Jeanne M Clark; Frederick L Brancati; Anna Mae Diehl
Journal:  Gastroenterology       Date:  2002-05       Impact factor: 22.682

4.  Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

Authors:  P Angulo; J C Keach; K P Batts; K D Lindor
Journal:  Hepatology       Date:  1999-12       Impact factor: 17.425

5.  Hepatic iron and nonalcoholic fatty liver disease.

Authors:  Z M Younossi; T Gramlich; B R Bacon; C A Matteoni; N Boparai; R O'Neill; A J McCullough
Journal:  Hepatology       Date:  1999-10       Impact factor: 17.425

6.  Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease.

Authors:  I R Willner; B Waters; S R Patil; A Reuben; J Morelli; C A Riely
Journal:  Am J Gastroenterol       Date:  2001-10       Impact factor: 10.864

7.  Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects.

Authors:  C Loguercio; V De Girolamo; I de Sio; C Tuccillo; A Ascione; F Baldi; G Budillon; L Cimino; A Di Carlo; M P Di Marino; F Morisco; F Picciotto; L Terracciano; R Vecchione; V Verde; C Del Vecchio Blanco
Journal:  J Hepatol       Date:  2001-11       Impact factor: 25.083

8.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

9.  Nonalcoholic steatohepatitis: an expanded clinical entity.

Authors:  B R Bacon; M J Farahvash; C G Janney; B A Neuschwander-Tetri
Journal:  Gastroenterology       Date:  1994-10       Impact factor: 22.682

10.  The natural history of nonalcoholic fatty liver: a follow-up study.

Authors:  M R Teli; O F James; A D Burt; M K Bennett; C P Day
Journal:  Hepatology       Date:  1995-12       Impact factor: 17.425

View more
  16 in total

1.  Histological resolution of steatohepatitis after iron depletion.

Authors:  Arnoldo Riquelme; Alejandro Soza; Leyla Nazal; Gabriel Martínez; Marianne Kolbach; Alejandro Patillo; J Marcos Arellano; Ignacio Duarte; Jorge Martínez; Monserrat Molgó; Marco Arrese
Journal:  Dig Dis Sci       Date:  2004-06       Impact factor: 3.199

2.  Non-alcoholic fatty liver disease: is iron relevant?

Authors:  Julia O'Brien; Lawrie W Powell
Journal:  Hepatol Int       Date:  2011-08-12       Impact factor: 6.047

3.  HFE mutations analysis of Turkish patients with nonalcoholic steatohepatitis.

Authors:  Halis Simsek; Yasemin H Balaban; Hale Sümer; Engin Yilmaz; Gonca Tatar
Journal:  Dig Dis Sci       Date:  2006-10       Impact factor: 3.199

Review 4.  Clinical features of pediatric nonalcoholic fatty liver disease: a need for increased awareness and a consensus for screening.

Authors:  Jeremy P Middleton; R Constance Wiener; Barrett H Barnes; Matthew J Gurka; Mark D DeBoer
Journal:  Clin Pediatr (Phila)       Date:  2014-01-28       Impact factor: 1.168

5.  Effect of iron on cholesterol 7α-hydroxylase expression in alcohol-induced hepatic steatosis in mice.

Authors:  Huan Liang; Hui Huang; Pei-Zhu Tan; Ying Liu; Jun-Hui Nie; Yi-Tong Zhang; Kai-Li Zhang; Yan Diao; Qi He; Bao-Yu Hou; Ting-Ting Zhao; Yan-Ze Li; Gui-Xiang Lv; Ki-Young Lee; Xu Gao; Ling-Yun Zhou
Journal:  J Lipid Res       Date:  2017-05-23       Impact factor: 5.922

6.  Comparative redox status in alcoholic liver disease and nonalcoholic fatty liver disease.

Authors:  Payal Bhardwaj; Kaushal Madan; Sandeep Thareja; Yogendra Kumar Joshi; Anoop Saraya
Journal:  Hepatol Int       Date:  2008-02-27       Impact factor: 6.047

7.  Peroxisome proliferator activated receptor-gamma in pathogenesis of experimental fatty liver disease.

Authors:  Cai-Yan Zhao; Ling-Ling Jiang; Li Li; Zhuo-Jun Deng; Bao-Li Liang; Jian-Mei Li
Journal:  World J Gastroenterol       Date:  2004-05-01       Impact factor: 5.742

8.  FXR agonist INT-747 upregulates DDAH expression and enhances insulin sensitivity in high-salt fed Dahl rats.

Authors:  Yohannes T Ghebremariam; Keisuke Yamada; Jerry C Lee; Christine L C Johnson; Dorothee Atzler; Maike Anderssohn; Rani Agrawal; John P Higgins; Andrew J Patterson; Rainer H Böger; John P Cooke
Journal:  PLoS One       Date:  2013-04-04       Impact factor: 3.240

Review 9.  Iron overload and cofactors with special reference to alcohol, hepatitis C virus infection and steatosis/insulin resistance.

Authors:  Yutaka Kohgo; Katsuya Ikuta; Takaaki Ohtake; Yoshihiro Torimoto; Junji Kato
Journal:  World J Gastroenterol       Date:  2007-09-21       Impact factor: 5.742

Review 10.  Pathogenesis and management issues for non-alcoholic fatty liver disease.

Authors:  Marko Duvnjak; Ivan Lerotić; Neven Barsić; Vedran Tomasić; Lucija Virović Jukić; Vedran Velagić
Journal:  World J Gastroenterol       Date:  2007-09-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.